drugset / Trial / NCT06913777
Neoadjuvant SNF Precision Therapy Phase III
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial designed to compare the efficacy and safety of neoadjuvant chemotherapy based on SNF classification with or without precision medicine agents in previously untreated patients with early-stage or locally advanced HR+/HER2- breast cancer.
Timeline
- Start
- 2025-04-08
- Primary completion
- 2026-10-15
- Completion
- 2027-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Subject | Famitinib | Small molecule | — | — |
| Subject | Fluzoparib | Small molecule | — | — |
| Subject | Rivoceranib | Small molecule | — | — |
Indications
No indication recorded.